The primary adverse reactions associated with intravesical injection of type A botulinum toxin typically encompass urinary tract infections (occurring in approximately 18% of cases), voiding difficulties (seen in around 9% of cases), and urinary retention (noted in approximately 3%–6% of cases), which tend to gradually resolve over time.[11] In this study, there were 5 cases of hematuria (13.51%), 4 cases of urinary tract infection (10.81%), and 1 case of urinary retention (2.7%), which required indwelling catheterization and drug treatment. Here, SGCG is linked to urinary tract infection.